ATE297204T1 - Heilmittel für neurodegenerative krankheiten - Google Patents

Heilmittel für neurodegenerative krankheiten

Info

Publication number
ATE297204T1
ATE297204T1 AT98961430T AT98961430T ATE297204T1 AT E297204 T1 ATE297204 T1 AT E297204T1 AT 98961430 T AT98961430 T AT 98961430T AT 98961430 T AT98961430 T AT 98961430T AT E297204 T1 ATE297204 T1 AT E297204T1
Authority
AT
Austria
Prior art keywords
neurodegenerative diseases
remedies
disease
medicament
present
Prior art date
Application number
AT98961430T
Other languages
English (en)
Inventor
Yoshinobu Masuda
Yoshiaki Ochi
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18494113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE297204(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Application granted granted Critical
Publication of ATE297204T1 publication Critical patent/ATE297204T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98961430T 1997-12-26 1998-12-21 Heilmittel für neurodegenerative krankheiten ATE297204T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP36931397 1997-12-26
PCT/JP1998/005757 WO1999033465A1 (en) 1997-12-26 1998-12-21 Remedy for neurodegenerative diseases___________________________

Publications (1)

Publication Number Publication Date
ATE297204T1 true ATE297204T1 (de) 2005-06-15

Family

ID=18494113

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98961430T ATE297204T1 (de) 1997-12-26 1998-12-21 Heilmittel für neurodegenerative krankheiten

Country Status (12)

Country Link
US (1) US6342515B1 (de)
EP (1) EP1040830B1 (de)
JP (1) JP3364481B2 (de)
KR (1) KR100508393B1 (de)
CN (1) CN1149084C (de)
AT (1) ATE297204T1 (de)
CA (1) CA2317044C (de)
DE (1) DE69830512T2 (de)
ES (1) ES2244103T3 (de)
HK (1) HK1029043A1 (de)
PT (1) PT1040830E (de)
WO (1) WO1999033465A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1332363A4 (de) * 2000-10-09 2007-08-29 Kay Double Nachweis neurodegenerativer erkrankungen
US7109198B2 (en) * 2002-05-17 2006-09-19 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
EP1539145A2 (de) * 2002-09-13 2005-06-15 Eisai Co., Ltd. Verfahren zur behandlung von tremor
US20050059718A1 (en) * 2003-02-21 2005-03-17 Hayato Miyachi Methods of using zonisamide as an adjunctive therapy for partial seizures
EP2316456B1 (de) 2003-04-29 2017-06-14 Orexigen Therapeutics, Inc. Zubereitungen enthaltend einen Opioidantagonisten und Bupropion zur Beeinflussung von Gewichtsverlust
US20050043773A1 (en) * 2003-08-21 2005-02-24 Ivan Lieberburg Methods of improving the safety of zonisamide therapy
US20050043704A1 (en) * 2003-08-21 2005-02-24 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154034A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154032A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154033A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154036A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154037A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154035A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
EP1913935A1 (de) * 2005-01-21 2008-04-23 Teva Pharmaceutical Industries Ltd Stabile pharmazeutische Zusammensetzungen von Zonisamide und Verfahren zur deren Herstellung
DE602006014607D1 (de) * 2005-01-21 2010-07-15 Teva Pharma Stabile pharmazeutische Zusammensetzungen von Zonisamide und Verfahren zur deren Herstellung
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
EP1951212A2 (de) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Zusammensetzungen und verfahren zur erhöhung der insulinsensitivität
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
TW201811315A (zh) 2006-11-09 2018-04-01 美商歐瑞根治療有限公司 層狀醫藥調配物
KR20090090316A (ko) 2006-11-09 2009-08-25 오렉시젠 세러퓨틱스 인크. 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
WO2009054543A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists and zonisamide for parkinson's disease and movement disorders
NZ589304A (en) 2008-04-29 2012-03-30 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
EP4104824A1 (de) 2012-06-06 2022-12-21 Nalpropion Pharmaceuticals LLC Zusammensetzung zur verwendung in einem verfahren zur behandlung von übergewicht und fettleibigkeit bei patienten mit hohem kardiovaskulärem risiko
JP6155266B2 (ja) * 2012-08-01 2017-06-28 大日本住友製薬株式会社 ゾニサミドを含有する経皮吸収型製剤
WO2014119767A1 (ja) * 2013-01-31 2014-08-07 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
US20180271838A1 (en) * 2015-09-30 2018-09-27 National University Corporation Nagoya University Pharmaceutical composition for treating and/or preventing peripheral neuropathy or spinal cord injury
EP3668508A1 (de) 2017-08-19 2020-06-24 FTF Pharma Private Limited Orale pharmazeutische zusammensetzung mit zonisamid und verfahren zur herstellung davon
EP3928771A1 (de) * 2020-06-23 2021-12-29 Laboratorios Lesvi, S.L. Pharmazeutische zusammensetzungen von 1,2-benzisoxazol-3-methansulfonamid
US20230202991A1 (en) 2020-07-07 2023-06-29 Sumitomo Pharma Co., Ltd. Benzisoxazole derivative
JP7324953B2 (ja) * 2022-01-12 2023-08-10 住友ファーマ株式会社 ベンゾイソキサゾール誘導体を含有する医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
WO1989006129A1 (en) * 1987-12-29 1989-07-13 Dainippon Pharmaceutical Co., Ltd. Agent for treating ischemic brain trouble
US5830910A (en) * 1995-10-23 1998-11-03 University Of Kentucky Research Foundation Cytochalasins useful in providing protection against nerve cell injury associated with neurodegenerative disorders

Also Published As

Publication number Publication date
KR100508393B1 (ko) 2005-08-17
EP1040830B1 (de) 2005-06-08
EP1040830A4 (de) 2002-10-23
CA2317044A1 (en) 1999-07-08
HK1029043A1 (en) 2001-03-23
DE69830512D1 (de) 2005-07-14
KR20010015890A (ko) 2001-02-26
CN1283113A (zh) 2001-02-07
EP1040830A1 (de) 2000-10-04
DE69830512T2 (de) 2006-03-23
JP3364481B2 (ja) 2003-01-08
CN1149084C (zh) 2004-05-12
ES2244103T3 (es) 2005-12-01
WO1999033465A1 (en) 1999-07-08
US6342515B1 (en) 2002-01-29
PT1040830E (pt) 2005-08-31
CA2317044C (en) 2008-02-26

Similar Documents

Publication Publication Date Title
ATE297204T1 (de) Heilmittel für neurodegenerative krankheiten
KR920019342A (ko) 골질환 치료제
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
ES2136723T3 (es) Utilizacion de n-aril-metilen-etilen-diamino-triacetatos, n-aril-metilen-imino-diacetatos o n,n'-diaril-metilen-etilen-diamino-acetatos contra el estres oxidante.
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
IL113941A (en) Perfluoroalkyl ketone inhibitors of elastase processes for making the same and pharmaceutical compositions containing them
HUP0104709A2 (hu) Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
ATE121295T1 (de) Augentropfenarzneimittel.
BG105302A (en) Means for improving cognition
FI972308A (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
EP0744176A3 (de) Arzneimittel zur Hemmung von Knochenschwund
AU4568400A (en) Sphingomyelinase inhibitor
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
FR2786100B1 (fr) Nouvelle application therapeutique de la nicergoline
EP0373771A3 (de) Neue pharmazeutische Anwendungen von Cystatinen
GB9126874D0 (en) Medicaments
BR9915292A (pt) Associação, utilização de riluzol e composição farmacêutica.
DE69928685D1 (de) Heilmittel und/oder vorbeugungsmittel gegen fettleibigkeit

Legal Events

Date Code Title Description
EEFA Change of the company name
UEP Publication of translation of european patent specification

Ref document number: 1040830

Country of ref document: EP